0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
4
Media Outlet Article / Coverage
ASCO Daily News
Published in print at ASCO Annual
Meeting
How Do Recent Approvals of Bispecific Antibodies Impact
Advanced Lung Cancer Management?
Features Abdul Rafeh Naqash, MD, SCRI at OU Health Stephenson Cancer Center
BioPharma Dive Bispecific Cancer Drugs, Data Caveats and Funding Alarms: 3
Takeaways From ASCO
Features Abdul Rafeh Naqash, MD, SCRI at OU Health Stephenson Cancer Center
FirstWord Pharma KOL Views Q&A: NSCLC at (and Around) ASCO
Melissa Johnson, MD
SCRI
Media Outlet Article / Coverage
American Journal of Managed
Care
Multicancer Detection Assays Remain Largely Elusive for Early-Stage
Disease Detection
Discover Pharma
Harbinger Health Presents Early Cancer Detection Data for High-Risk
Populations at ASCO 2025
Managed Healthcare Executive
Multicancer Detection Assays Not Quite Ready for Prime Time in Early
Cancers | ASCO 2025
Precision Medicine Online MCED Developers Share New Data at ASCO as Stakeholders
Weigh Harms and Benefits
Targeted Oncology
Blood-Based Cancer Detection Test Shows Promise in High-Risk
Populations
Dax Kurbegov, MD
HCA Healthcare Sarah Cannon Cancer Network
Media Outlet Article / Coverage
VuMedi
ASCO® 2025 Summary: Top Breast Cancer Updates Including
SERENA-6 and DESTINY-Breast09 Trials
VuMedi
ASCO® 2025 Insights: Vepdegestrant, a PROTAC ER Degrader, vs.
Fulvestrant in ER+/HER2- Advanced BC - Results of the Global,
Randomized, Phase 3 VERITAC-2 Study
Erika Hamilton, MD
SCRI
